Yuichi Kitai

TL;DR: In this article, the authors show that TPT-treated cancer cells release exosomes that contain DNA that activate dendritic cells via STING signaling, and that a STING-dependent pathway drives antitumor immunity by responding to tumor cell-derived DNA.

TL;DR: It is shown that treatment of breast cancer cells with the antitumor agent topotecan (TPT), an inhibitor of topoisomerase I, induces danger-associated molecular pattern secretion that triggers dendritic cell activation and cytokine production, suggesting that a STING-dependent pathway drives antitumors immunity by responding to tumor cell–derived DNA.

TL;DR: Novel in vitro data from normal human keratinocytes are presented that would help elucidating the IL-17A-driven keratinocyte activation in psoriasis.

TL;DR: It is suggested that ATP6V0D2-dependent intravesicular acidification is required for TLR4 internalization, which is associated with prevention from excessive LPS-triggered inflammation and induction of tolerance.

TL;DR: It is shown that STAP-2 promotes tumorigenesis of prostate cancer cells through up-regulation of EGF receptor (EGFR) signaling and enhances its stability by inhibiting c-CBL–mediated EGFR ubiquitination.